SAN DIEGO , Nov. 4, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences: 21st Annual Industry/Academia Precision Oncology & Radmed Symposium November 5 th, 2025 – La Jolla, California Title: DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal Cancer and Ewings Sarcoma Format: Presentation Presenters: Josep Garcia, PhD, Executive Vice President, Chief Clinical Development Officer, Inhibrx; Katelyn Willis, PhD, Director, Biotherapeutics, Inhibrx Date: Wednesday, November 5 th, 2025 Time: 4:45 PM Eastern Standard Time Location: The Alexandria at Torrey Pines, La Jolla, California Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting November 12 th – 15th, 2025 – Boca Raton, Florida Title: The Tetravalent Death Receptor 5 (DR5) Agonist ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results from the Randomized, Registrational, Phase 2 ChonDRAgon Study Lead Author: Robin L. Jones, MD – Medical Oncology, The Royal Marsden and Institute of Cancer Research Format: Presentation Date: Friday, November 14th, 2025 Time: 8:30 AM – 10:00 AM Eastern Standard Time Location: The Boca Raton, Boca Raton, Florida Society for NeuroOncology (SNO) 2025 Annual Meeting November 19 th – 23rd, 2025 – Honolulu, Hawaii Title: The Tetravalent Death Receptor 5 (DR5) agonist ozekibart (INBRX-109) exhibits anti-tumor activity in GBM models as a monotherapy and in combination with TMZ Format: Poster Presentation Date: Saturday, November 22 nd, 2025 Time: 4:45 pm – 6:00 PM Eastern Standard Time Location: Hawaii Convention Center, Honolulu, Hawaii; Kamehameha Exhibit Hall II & III The presentation and poster will be accessible through a link on the investors' section of Inhibrx's website at https://inhibrxbiosciences.investorroom.com/events-and-presentations upon commencement of each event.
